ARTICLE | Company News
Verastem grants CSPC rights to Copiktra in China
September 25, 2018 10:43 PM UTC
Verastem Inc. (NASDAQ:VSTM) granted CSPC Pharmaceutical Group Ltd. (HKSE:1093) exclusive rights to develop and commercialize cancer drug Copiktra duvelisib in China, including Hong Kong and Macau, and Taiwan.
On Monday, Copiktra became the first dual phosphoinositide-3-kinase (PI3K) δ and γ inhibitor to gain FDA approval, according to Verastem (see "FDA Approves Verastem's Duvelisib")...